S9 Ep9: FDA Approval Insights: Avapritinib in Indolent Systemic Mastocytosis

from OncLive® On Air · host OncLive® On Air

Dr Gotlib discusses the significance of the FDA approval of avapritinib in indolent systemic mastocytosis, key findings from the PIONEER trial, and the quality of life benefits that avapritinib provides for patients in this population.

Episode metadata supplied by the publisher feed · Published Jul 10, 2023

Embed this episode

Attribution link and audio player

NOW PLAYING

S9 Ep9: FDA Approval Insights: Avapritinib in Indolent Systemic Mastocytosis

0:00 13:53

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of OncLive® On Air?

This episode is 13 minutes long.

When was this OncLive® On Air episode published?

This episode was published on July 10, 2023.

Can I download this OncLive® On Air episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!